Latest Administration News

Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.

Santos Limited reports a stable 2025 reserves position with a 17-year life and significant growth in CO2 storage capacity, underpinning its decarbonisation strategy. The company also provides preliminary guidance on its 2025 financial results.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

Brightstar Resources has launched a $5 million Share Purchase Plan offering eligible shareholders discounted shares to fund key mining projects. The offer opens on 10 February and closes on 27 February 2026.

Regal Partners Global Investments Limited has updated its Dividend Reinvestment Plan to reflect its recent rebranding and remove participation barriers, effective immediately for the 1H26 interim dividend.

American Uranium Limited has upgraded its U.S. trading status to the OTCQB Venture Market, enhancing liquidity and accessibility for North American investors. This move supports the company’s strategy to expand its U.S. shareholder base and increase visibility for its flagship uranium project in Wyoming.

Sims Limited is consolidating its Houston footprint by acquiring Tri Coastal Trading assets and selling its Mayo Shell property, aiming to boost EBITDA and cut costs significantly.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

Lindian Resources has placed orders for critical long-lead plant equipment and accelerated construction at its Kangankunde Rare Earths Project, targeting first ore feed by November 2026.